european dermaportation patent, page-35

Hi Pman,

"Here is an opportunity to put out an announcement that is positive and good PR for the company, yet it's left to the Hotcopper community to dig to make the announcement. Every piece of progress is pr for the company. They need to get that into there scientific skulls."

I'm quite surprised how many here agree with that opinion given that we were provided the obvious clue with the arrival of the Procter & Gamble announcement back in May, which restricted the company from making any further mention of our Dermaportation IP - And without any doubt this would have applied to both the US and our imminent EPO allowance.

Perhaps all the negative talk has been deluding people to the fact that it is most likely we will very soon see the arrival of a material licensing agreement before we receive anything from the company relating to that EPO patent grant?

Let me show you exactly where I'm coming from:

23/08/2011: US Patent Office Allows Dermaportation Patent
03/11/2011: US Patent Granted

28/02/2012: Appendix 4D 31 Dec 2011 (Full Copy)

Commercial Activities
OBJ remains committed to its three-part commercial development program which focuses on partnering with major international pharmaceutical, cosmetic and FMCG companies, developing value added products and processes utilising OBJ’s proprietary design and development of its range of products to be distributed by channel partners.

The Company received notification from the US Patent Office in August 2011 that its Dermaportation or powered technology device patent had been allowed. This has subsequently allowed the Company to gain considerable interest from major cosmetic groups for the Company’s new e-skin product range. The potential market exclusivity provided by the US patent has considerably strengthened market interest.

In October, the Company learned that the FMCG company was seeking world-wide exclusive access rights to OBJ’s technologies in the area of a beauty. Negotiations commenced regarding the various financial, developmental and investment commitments by the FMCG company to OBJ’s technologies and considerable progress in these negotiations was achieved during the period.

And as the financial part of those negotiations would be related to P&G securing the access rights to our granted US patent, and a soon to be granted European patent for our Dermaportation technology, one would have to assume that confidentiality agreements will restrict OBJ from making any further mention of our Dermaportation patents until the material license details have been announced to the market.

18/05/2012: Procter and Gamble Enters Joint Development Agreement
We warmly welcome the collaboration with Procter & Gamble and congratulate the technical and marketing team for this achievement.

Note: The company can't really congratulate the 'Commercial team' until the financial details of the exclusive licence deal has been announced - and for what reason might we be waiting for the $$$ details?

Jeff Weedman - P&G Director Global External Business Development
Not surprisingly, we like there to be strong robust IP or the opportunity to do that fairly quickly. Putting it simply, why should I pay for something that is not protected? - Source

15/08/2012: Shareholder Update
Note: No mention of Dermaportation patents

30/08/2012: Appendix 4E
Note: No mention of Dermaportation patents

27/09/2012: Annual Report 2012
Note: Yes, we understand that both the allowance and grant of our US Dermaportation patent by the USPTO were announced during this reporting period, and it represents one of, if not the most commercially significant event in the company's history, but no can do, sorry

Welcome to the real world of confidentiality agreements - We must stop comparing OBJ to all the wannabe's which claim to sign NDA agreements, but wouldn't be worth the paper they're written on.

If I can borrow a couple of words in AMG's recent email from Glyn - And it is important to be reminded of Glyn's very conservative style of delivery...

The advice that we have signed a Joint Development Agreement with Proctor and Gamble and the possibilities that may transpire from that arrangement has come about after three years of really hard work. It may not be well appreciated in some quarters just how difficult a task it is to execute an arrangement such as this with one of the world’s major pharmaceutical and skin care company. And these companies do not enter into such agreements without serious intent.

So we are looking forward to the future which is set up after many years of endeavor and as events unfold we will so continue to advise the market.

If this is still not clear enough one can also go back and read our 2010 AGM Presentation

From this ridiculously low share price, strap yourself in mate - Hope you're not scared of heights ;)